Scarica l'app Stockscreener
10.75
4.62%
0.475
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.28
Aprire:
$10.38
Volume 24 ore:
731.61K
Relative Volume:
0.96
Capitalizzazione di mercato:
$739.72M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-5.9066
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-1.29%
1M Prestazione:
+3.76%
6M Prestazione:
+69.29%
1 anno Prestazione:
+28.59%
Intervallo 1D:
$10.16
$10.88
Intervallo di 1 settimana:
$9.5101
$10.88
Portata 52W:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
10.75 | 708.23M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $41 - 富途牛牛
EyePoint Completes Enrollment for Phase 3 Trials - MSN
Analysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest Results - 富途牛牛
EyePoint Pharmaceuticals Sees Analyst Expectations Lowered After Disappointing Q2 Results - AInvest
How did EYPT's revenue streams evolve in Q4 2024? - AInvest
EyePoint (EYPT) Q2 Revenue Drops 44% - AOL.com
EyePoint Pharma: Clinical Progress Amid Financial Hurdles - AInvest
EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment - MSN
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected at $6.63 Million - AInvest
EyePoint Pharmaceuticals Reports Q2 2025 Financial Results, Highlights Recent Developments and Milestones - AInvest
EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges - TipRanks
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating - TipRanks
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI - TipRanks
EyePoint Pharmaceuticals (EYPT) Receives Updated Analyst Ratings | EYPT Stock News - GuruFocus
EyePoint reports Q2 EPS (85c), consensus (80c) - TipRanks
Earnings call transcript: Eyepoint Pharmaceuticals Q2 2025 sees revenue miss, stock drops - Investing.com India
EyePoint Pharmaceuticals Drops 10.38% on Q2 Loss, Clinical Progress - AInvest
EyePoint Pharmaceuticals Inc Reports Q2 2025 Earnings: EPS of ($ - GuruFocus
EyePoint Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmol - GuruFocus
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
EyePoint Q2 revenue falls 44%, net loss widens - MarketScreener
EyePoint Pharmaceuticals CEO Reveals Latest Retinal Disease Breakthroughs at Major Ophthalmology Conference - Stock Titan
EyePoint Reports Second Quarter 2025 Financial Results and Highl - GuruFocus
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint's DURAVYU Phase 3 Trials Break Enrollment Records: 800+ Wet AMD Patients in Just 7 Months - Stock Titan
EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Prev - GuruFocus
EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
What drives EyePoint Pharmaceuticals Inc. stock priceTake advantage of unprecedented market momentum - Jammu Links News
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyMaximize portfolio growth with strategic plans - Jammu Links News
What is EyePoint Pharmaceuticals Inc. company’s growth strategyPhenomenal trading returns - Jammu Links News
Does EyePoint Pharmaceuticals Inc. stock perform well during market downturnsMaximize returns with strategic trading plans - Jammu Links News
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025Achieve breakthrough growth with proven strategies - Jammu Links News
Why is EyePoint Pharmaceuticals Inc. stock attracting strong analyst attentionBreakout profit opportunities - Jammu Links News
How volatile is EyePoint Pharmaceuticals Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News
What catalysts could drive EyePoint Pharmaceuticals Inc. stock higher in 2025Navigate market shifts with confidence - Jammu Links News
Is EyePoint Pharmaceuticals Inc. stock overvalued or undervaluedMassive portfolio appreciation - Jammu Links News
What are EyePoint Pharmaceuticals Inc. company’s key revenue driversAccelerated wealth expansion - Jammu Links News
Is it the right time to buy EyePoint Pharmaceuticals Inc. stockFree Investment Community - Jammu Links News
What analysts say about EyePoint Pharmaceuticals Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate EyePoint Pharmaceuticals Inc. as a “Buy”Rapid wealth creation - Jammu Links News
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
EyePoint Pharmaceuticals: Positive Buy Rating Based on Promising Clinical Trials and Market Valuation - AInvest
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
EyePoint Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Retinal Disease Pipeline - Stock Titan
Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Accuracy Alerts for ROI Traders Detected - metal.it
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):